![Jennifer Taubert, chair of J&J's worldwide innovation group](/sites/default/files/styles/x_large/public/2024-07/jennifer-taubert-JNJ.jpg?itok=CY6yBzix)
J&J IRA pricing offer is in, as it sticks with 2025 guidance...
Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances nex